血清肿瘤标志物联合检测在肺部良恶性病变诊断中的价值

The value of combined detection of serum tumor markers in the diagnosis of benign and malignant lung diseases

目的:探讨血清肿瘤标志物联合检测在肺部良恶性病变诊断中的相关价值。方法:2018年1-12月收治肺部疾病患者60例,其中肺部恶性肿瘤患者30例作为观察组,肺部良性病变患者30例作为对照组。对两组患者CEA、细胞角蛋白19片段、鳞状细胞癌相关抗体、胃泌素释放肽前体、CA19-9、CA125、CA15-3、血清肿瘤相关物质等肿瘤标志物含量进行测定并比较。结果:观察组血清肿瘤标志物CEA、细胞角蛋白19片段、胃泌素释放肽前体含量显著高于对照组,差异有统计学意义(P<0.05)。两组鳞状细胞癌相关抗体、CA125、CA19-9、CA15-3、血清肿瘤相关物质水平比较,差异无统计学意义(P>0.05)。结论:肿瘤标志物CEA、细胞角蛋白19片段、胃泌素释放肽前体,在肺部良恶性病变诊断中应用价值显著,适用于临床恶性肺部肿瘤鉴定。鳞状细胞癌相关抗体、CA125、CA19-9、CA15-3、血清肿瘤相关物质筛查则对于肺部良恶性肿瘤鉴别无明显价值。

Objective:To explore the correlation value of CEA,cytokeratin 19 fragment,squamous cell carcinoma related antibody,gastrin releasing peptide precursor,CA19-9,CA125,CA15-3,serum tumor related substances screening and other tumor markers in the diagnosis of lung benign and malignant lesions.Methods:From January to December 2018,we admitted 60 patients with lung diseases,30 patients with lung cancer were treated as the observation group and 30 patients with lung benign lesions were treated as the control group.We measured and compared the levels of related tumor markers between the two groups.Results:In the observation group,CEA,cytokeratin 19 fragment and gastrin releasing peptide precursor were significantly higher than those in the control group,the difference was statistically significant(P<0.05).There was no significant difference in squamous cell carcinoma related antibodies,CA125,CA19-9,CA15-3,serum tumor related substances between the two groups(P>0.05).Conclusion:The application value of CEA,cytokeratin 19 fragment and gastrin releasing peptide precursor in the diagnosis of lung benign and malignant lesions was significant,they were suitable for the identification of clinical malignant lung tumors.